Q-omics provides the consensus-scored EI24 profile across patient tissues and cancer cell-line models. EI24 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, EI24 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, EI24 RNA expression shows 18,816 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where EI24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EI24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EI24 survival associations across molecular data types. EI24 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EI24 RNA expression–survival associations across cancer types. High EI24 expression shows unfavorable associations in ACC, MESO, PAAD, LAML, KICH and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for EI24 RNA expression.
This table summarizes EI24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for EI24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EI24 shows higher tumor expression in HNSC, LUSC, STAD, BLCA, LUAD and COAD. The HNSC box plot shows higher EI24 RNA expression in tumor versus normal tissue (log2 FC = +0.564, t-test p < 0.001).
This table shows molecular features associated with EI24 in patient tissues and cancer cell lines. In patient samples, EI24 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, EI24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
